Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 46, 2022 - Issue 6
85
Views
0
CrossRef citations to date
0
Altmetric
Brief Reports

Severe Hb H Disease Caused by Hb Zürich–Albisrieden (HBA1: c.178G>C): Another Case Report

, , , &
Pages 341-343 | Received 15 Nov 2022, Accepted 22 Dec 2022, Published online: 23 Feb 2023
 

Abstract

Hb Zürich–Albisrieden, [α59(E8)Gly→Arg, HBA1: c.178G>C] is a rare and highly unstable α-globin chain variant. The involved mutation has been reported in both HBA1 and HBA2 genes. A few compound heterozygotes of Hb Zürich–Albisrieden and α0-thalassemia have shown that this variant is associated with severe Hb H disease. We describe here another case of Hb Zürich–Albisrieden who presented with transfusion-dependent anemia beginning shortly after birth.

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Figure 1. Sanger sequencing chromatograms of the HBA1 gene show the c.178G > C (arrow) mutation in the son (upper) and his mother (lower).

Figure 1. Sanger sequencing chromatograms of the HBA1 gene show the c.178G > C (arrow) mutation in the son (upper) and his mother (lower).

Additional information

Funding

This study was supported by the Provincial Department of Science and Technology Agency of Guangdong [2021A1515220088], Guangdong Province, People’s Republic of China.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.